15 Posts From ASCO 2024 Day 4 You Should Not Miss!
Karen Knudsen, MBA PhD Zainab Shinkafi-Bagudu Toni Choueiri, MD Andrea Necchi Bishal Gyawali Wafik S. El-Deiry, MD, PhD, FACP Jun Gong Jennifer Marks, MD Yüksel Ürün Sabine D. Brookman-May American Cancer Society Khalid El Bairi Yale Cancer Center Herbert Loong Conquer Cancer, the ASCO Foundation
oncodaily.com/societies/7718…

Excellent coverage on lymph-node only metastatic #UrothelialCancer as a distinct entity among complete responders to Nivo/GC #CheckMate901
➡️Med OS in LN-only mUC: 46.3 (Nivo+GC) vs 24.9 months with GC (HR 0.58)
👉bit.ly/3VtnrVz Matt Galsky UroToday.com OncoDaily
#ASCO24

Updates from the EV-302 study:
Patient reported outcomes indicate meaningful improvements in pain score and overall quality of life favoring EV+P vs. chemotherapy.
Great presentation by Shilpa Gupta !
ASCO Cleveland Clinic

It is an important topic and we need solutions for #ProstateCancer patients how to best reduce hot flashes, anxiety, depression
👉 #PhysicalExercise and #VagusStimulation may be options to explore further
👉Maintenance is key for continuous results, which remains a challenge

While it is great to see studies evaluating the impact of #BMI on oncological #outcomes , limitations of BMI are obvious
👉We need data under consideration of visceral fat, %fat-free mass/muscle, PhysicalExercise, which has been shown to improve outcomes #ProstateCancer

Such important work! Use of PPI and antibiotics is associated with worse OS/PFS in patients with #mUC treated with #ICI
Antibiotics have a considerable impact on our immune system. In #cancer care we should even more consider their potential negative impact Shilpa Gupta Charbel Hobeika, MD

Here we go with our Università Vita-Salute San Raffaele medical student Giovanni Pastorino presenting #NureCombo neoadj trial biomarker data. Congratulations the future is bright! Ospedale San Raffaele Chiara Mercinelli Antonio Cigliola Valentina Tateo ASCO #ASCO24 UroToday.com

Tumor fraction and copy number burden using #utDNA may be an excellent biomarker for minimal residual disease #MRD to be used for surveillance in high-risk #NMIBC #BladderCancer
Josh Linscott Roger Li

Tom Powles The question is also which are the parameters + #QoL aspects we need to show differences? What is most important for #patients ? What are the right time points to assess differences over time? Right now we don’t have the perfect tools especially not for early stage GU #cancers

SURE-01: neoadj SG +/- pembro in #MIBC #ASCO24
✅ 36% pCR/45% ypT≤1N0 (RC) + 6/7 pts refusing RC with clinical CR (MRI/cysto/ctDNA/TURBT-)
👉 potential #BladderSparing approach?
🔹Proper AE management required #GCSF
OncoDaily UroToday.com Andrea Necchi Antonio Cigliola ASCO

🟠The AURA trial found adding avelumab to neoadjuvant chemo for muscle-invasive urothelial carcinoma improved 36-month DFS (77%) and OS (87%) in cisplatin-eligible patients. No benefit was seen in cisplatin-ineligible patients. Avelumab shows promise in the perioperative setting.

Chromophobe RCC: Multicenter analysis of 1L systemic therapy options (n=102)
🔹TTF: Longest with VEGF-TKI + mTORi (lenva or beva + everolimus): 17 mo, followed by TKI + IO doublet: 15 mo
🔹OS: Longest with VEGF-TKI + mTORi: 99 mo, followed by TKI + IO doublet: 56 mo

UroToday.com

Great ctDNA work in advanced bladder cancer presented by Tom Powles
Is MRD arriving in advanced disease?

TROPICS-4 (sacituzumab govitecan vs chemo) in heavily pretreated bladder cancer missed OS. Many drugs have failed in this space (personal experience +++). Managing toxicity is important. Earlier treatment & combinations may yield different results #ASCO24 gilead.com/news-and-press…

It has been a pleasure to participate in #EAU EAU Young Urologists #TalentIncubator 1 + 2 and to contribute to this publication European Urology
I hope this editorial can provide guidance and kick-off some actions to develop the #urologist of the #future in the best way
authors.elsevier.com/a/1jAJK14kplyy…

Seeing such behavior in #Sylt from my distant US observation point, makes the #stupidity + ignorance of these people even more obvious. Possibly rich on money, poor on ethics, integrity, intelligence, #humanity
These are not Germans, they are #Sylt kröten, a species nobody likes

Intravesical erdafitinib demonstrates high response rates in #NMIBC with reduced toxicity. Roger Li and Sam S. Chang MD, MBA discuss the #TAR210 , share insights, and highlight the efficacy of Erdafitinib, particularly in patients with FGFR alterations > bit.ly/3w78L4p